In this video, Motley Fool health-care analyst David Williamson takes a look at Threshold's (NASDAQ: THLD) big week and the news on Friday that has shares soaring even higher. Find out what it means for investors in Threshold and competitor Celgene if MAESTRO is a success.
The new phase 3 trial is critical for the company.
David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.